Equities

Oncolytics Biotech Inc

ONCY:NAQ

Oncolytics Biotech Inc

Actions
  • Price (USD)0.9239
  • Today's Change-0.026 / -2.75%
  • Shares traded250.49k
  • 1 Year change-56.42%
  • Beta1.7984
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CAD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments353241
Total Receivables, Net0.020.520.87
Total Inventory------
Prepaid expenses3.253.032.78
Other current assets, total------
Total current assets383645
Property, plant & equipment, net0.650.650.98
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets393746
LIABILITIES
Accounts payable1.08----
Accrued expenses2.49----
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.130.220.29
Other current liabilities, total0.530.080.41
Total current liabilities4.243.952.69
Total long term debt0.290.160.36
Total debt0.420.370.65
Deferred income tax------
Minority interest------
Other liabilities, total6.736.736.73
Total liabilities11119.78
SHAREHOLDERS EQUITY
Common stock431404391
Additional paid-in capital424038
Retained earnings (accumulated deficit)(446)(418)(393)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.540.660.39
Total equity282736
Total liabilities & shareholders' equity393746
Total common shares outstanding746155
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.